Given that a possible antagonism between TPL2 and KSR1, as we aforementioned, TPL2-mediated alternative ERK1/2 activation may evade p53 and p16(ARF)-mediated senescence for tumor cell to continue proliferation. This evidence concerns the gene MAPK3 and neoplasm.